

Via Facsimile and U.S. Mail  
Mail Stop 6010

September 12, 2008

Ms. Rose C. Perri  
Generex Biotechnology Corp.  
Chief Financial Officer  
33 Harbour Square, Suite 202,  
Toronto, Ontario Canada M5J 2G2

**Re: Generex Biotechnology Corp.  
Item 4.01 Form 8-K  
Filed September 10, 2008  
File No. 000-25169**

Dear Ms. Perri:

We have reviewed your filing and have the following comments. Where indicated, we think you should revise your document in response to these comments. If you disagree, we will consider your explanation as to why our comment is inapplicable or a revision is unnecessary. Please be as detailed as necessary in your explanation. In some of our comments, we may ask you to provide us with more information so we may better understand your disclosure. After reviewing this information, we may raise additional comments.

Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter.

Item 4.01 Form 8-K

1. It appears that a change in accountant took place on August 1, 2008, the date the merger occurred between Danziger Hochman Partners LLP and MSCM LLP. Thus so being, it appears an Item 4.01 8-K was not filed within 4 business days of the date of the dismissal of your former auditors. Please note that this delinquency may impact your eligibility requirements for filing on Form S-3.
2. Your references to the “subsequent interim period preceding the engagement of MSCM” in the third paragraph is too vague. Please amend your filing to specifically state whether, during your past two fiscal years and in the subsequent interim period through August 1, 2008, the date of resignation, declination or dismissal there were any disagreements with the former accountant on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement(s), if not resolved to the satisfaction of the former accountant, would have caused it to make reference to the subject matter of the disagreement(s) in connection with its reports. You should specify the “interim period” as the “interim period through August 1, 2008,” which is the date Danziger Hochman Partners LLP ceased being your auditors.
3. It is unclear why the fourth paragraph has been included. Please advise or revise.
4. Your reference to the “subsequent interim period preceding the engagement of MSCM” in the fifth paragraph is too vague. Please amend your filing to specifically state whether, during your past two fiscal years through the date of engagement (September 5, 2008), you consulted MSCM, LLP regarding any of the matters outlined in Item 304(a)(2) of Regulation S-K. Ensure that your revised disclosure specifies whether you consulted MSCM LLP regarding any of the matter that was the subject of a reportable event during the aforementioned timeframe.
5. Upon amending your filing, please include, as Exhibit 16, an updated letter from your former accountants, Danziger Hochman Partners LLP, as required by Item 304(a)(3) of Regulation S-K. Please ensure that your former accountants date their letter.

\* \* \* \*

As appropriate, please amend your filing and respond to these comments within five business days or tell us when you will provide us with a response. You may wish to provide us with marked copies of the amendment to expedite our review. Please furnish a cover letter with your amendment that keys your responses to our comments and provides any requested information. Detailed cover letters greatly facilitate our review. Please understand that we may have additional comments after reviewing your amendment and responses to our comments.

Ms. Rose C. Perri  
Generex Biotechnology Corp.  
September 12, 2008  
Page 3

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes all information required under the Securities Exchange Act of 1934 and that they have provided all information investors require for an informed investment decision. Since the company and its management are in possession of all facts relating to a company's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

In connection with responding to our comments, please provide, in writing, a statement from the company acknowledging that:

- the company is responsible for the adequacy and accuracy of the disclosure in the filing;
- staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
- the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

In addition, please be advised that the Division of Enforcement has access to all information you provide to the staff of the Division of Corporation Finance in our review of your filing or in response to our comments on your filing.

If you have any questions, please do not hesitate to call me at (202) 551-3658.

Sincerely,

Tabatha Akins  
Staff Accountant